Finasteride for hair loss: evidence, risks and controversy

Key points

• Finasteride is approved in the US for male pattern hair loss, men only. In the label’s trials (1,879 men, 12 months) a blinded photo panel rated 48% of treated men as improved versus 7% on placebo [1].
• Sexual side effects were 3.8% with finasteride versus 2.1% with placebo in year 1 of those trials. Persistent sexual symptoms after stopping are on the US label as post-marketing reports, but their frequency is unknown [1].
• The EU (decision of 22 August 2025) confirmed suicidal ideation as a side effect, frequency unknown. The UK regulator added warnings on 11 May 2026 [2][3].
• Observational studies disagree on depression and suicide. The largest pooled analyses found no significant suicide link, and none can rule out a rare effect in a subgroup [6][7][8].
• On the @Hoostethics lists, the D tier misses the efficacy evidence, and “extremely cope” is a category error for a prescription drug. Verdict below [12].

What finasteride is

Finasteride blocks type II 5-alpha-reductase, an enzyme that converts testosterone to dihydrotestosterone (DHT). DHT is implicated in the shrinking of scalp follicles in male pattern hair loss (androgenetic alopecia) [4]. It is a prescription drug. The same molecule is sold at a higher strength for benign prostatic hyperplasia; this article concerns the hair-loss use. For other hair treatments see our articles on topical minoxidil and oral minoxidil.

Regulatory status

United States (FDA). The Propecia label (DailyMed version of 14 October 2024, manufacturer Organon) says it is indicated for “male pattern hair loss (androgenetic alopecia) in MEN ONLY” and is not indicated for women. Efficacy in bitemporal recession is not established [1]. It is prescription-only.

European Union (EMA). Finasteride 1 mg tablets and a finasteride skin spray, used for early androgenetic alopecia, were within the scope of an Article 31 review of finasteride and dutasteride. We read the EMA referral page; we did not read the national summaries of product characteristics [2].

United Kingdom (MHRA). We read the Drug Safety Update of 11 May 2026 (see below). We did not read the UK licensed-indication text [3].

Not checked: Germany (BfArM), any other national register.

What the pivotal trials found

The label describes three double-blind, randomized, placebo-controlled studies of 12 months in 1,879 men aged 18 to 41 with mild to moderate hair loss; two enrolled vertex-balding men (n=1,553) and one frontal mid-scalp loss (n=326) [1]. The published report of the two vertex trials (J Am Acad Dermatol, 1998) confirms 1,553 men, with 1,215 continuing to a second blinded year [4].

Measure (vertex trials)	Finasteride	Placebo
Hair count difference vs placebo, 12 months (1-inch circle)	+107 hairs	reference
Same, 2 years	+138 hairs	reference
Same, 5 years (219 vs 15 men remaining)	+277 hairs	reference
Blinded photo panel: improved, 12 months	48%	7%
Photo panel at 5 years: improved / no change / lost hair	48% / 42% / 10%	6% / 19% / 75%
Baseline count in the trial	876 hairs

Source: [1][4]. Counts are in a small marked area, not the whole scalp. The 5-year placebo arm shrank to 15 men, so the five-year contrast is a comparison of a large group with a very small one. Hair gains from the treatment fade after stopping: men switched from finasteride to placebo lost the gain within a year [1].

Funder. The label’s trials were conducted for the product’s manufacturer. The published 1998 abstract does not state a funder, and we could not open the full text or a funding statement, so we cannot confirm “Merck” from a document we read. Treat the results as manufacturer-run. One review in women (Cochrane, 2016) found finasteride no better than placebo in female pattern hair loss, low-quality evidence; the label does not cover women [11].

Sexual side effects in the trials

In the label’s three 12-month trials, drug-related decreased libido occurred in 1.8% versus 1.3%, erectile dysfunction in 1.3% versus 0.7%, and ejaculation disorder in 1.2% versus 0.7%. Pooled, 36 of 945 treated men (3.8%) had one or more of these, versus 20 of 934 on placebo (2.1%, p=0.04). The label states these resolved in men who stopped and in most who continued, and that each fell to 0.3% or less by year 5 [1].

These are one-year, mostly short-term, drug-related events in a trial population that was younger and healthy.

The persistent-symptoms debate

The current US label lists, as post-marketing reports, “sexual dysfunction that continued after discontinuation of treatment”, plus infertility or poor semen quality, depression, and suicidal ideation and behavior. It adds that such voluntary reports do not allow reliable frequencies or causation [1].

Advocates call the pattern post-finasteride syndrome (PFS). A 2022 expert panel proposed diagnostic criteria for enduring sexual dysfunction after finasteride, SSRIs and isotretinoin, built from two published case series [13]. A prospective follow-up of 54 self-referred men with persistent symptoms found 96% still reported them 9 to 16 months later [5]. That design cannot estimate how often this happens: it enrols people who already have symptoms and has no comparison group. A 2021 pooled analysis reported high rates of depressive symptoms and “sustained sexual dysfunction” (60.1%), but pooled heterogeneous reports of mixed design, and we treat its percentages as non-representative [14]. A 2016 systematic review noted uncommon persistent effects in a subset of younger men and the absence of long-term adverse-effect research [10].

What is not known: how common persistent symptoms are, who is at risk, and whether they are caused by the drug or by prior conditions, nocebo effects or the hair loss itself.

Regulators, with dates

Date	Regulator	Action
3 Oct 2024	EMA	Article 31 review started at the request of the French agency [2]
8 May 2025	EMA PRAC	Recommendation published (EMA/142716/2025) [2]
19 Jun 2025	CMDh	Position adopted by majority [2]
22 Aug 2025	European Commission	Final, binding decision [2]
11 May 2026	MHRA	Drug Safety Update: warnings and label changes [3]

EU. The review found suicidal ideation to be a side effect of finasteride 1 mg and 5 mg tablets, frequency unknown. EudraVigilance held 325 relevant cases (313 finasteride, 13 dutasteride, one both), against an estimated 270 million patient-years of exposure to finasteride. A patient card went into 1 mg packs, and information now tells patients to seek advice for sexual dysfunction, which may contribute to mood changes. No link was found for the skin spray. Benefits were judged to outweigh risks for all approved uses [2].

UK. Yellow Card recorded 170 reports of suicidal ideation and related terms with finasteride and 19 fatal suicide reports from 1994 to 31 May 2025. The MHRA states a report does not prove the medicine caused the event. Its advice is that finasteride is associated with depression, suicidal ideation and “sexual dysfunction which may persist after treatment is stopped” [3].

US. The current label carries the psychiatric and persistent sexual reports above [1]. Press and advocacy coverage places the addition of suicidal ideation in August 2022, but we did not open an FDA safety communication or the date of that label change, so we could not verify it.

Observational studies and their limits

• A Swedish register cohort (2,236,876 men, median start age 73, mostly prostate patients) found a higher depression hazard with finasteride (HR 1.61, 95% CI 1.48 to 1.75), but no significant suicide association (HR 1.22, CI 0.99 to 1.49) [6].
• A 2024 meta-analysis of five studies (2.2 million patients) found no significant link with depression (aHR 1.30, CI 0.85 to 2.00) or suicide (aHR 1.30, CI 0.65 to 2.61) [8].
• A 2026 meta-analysis of nine studies reported HR 1.07 (CI 0.76 to 1.51), heterogeneity I² = 59% [7].

The limits: most of these men took the prostate dose and were older than the typical hair-loss patient. Depression is common in people with hair loss, so confounding by indication is likely; register studies miss sexual symptoms; and wide intervals leave room for a modest risk. The evidence fits “no large population-level effect shown”, not “no effect in anyone”.

Topical finasteride

A 24-week phase III randomized trial in Europe (458 men, 45 sites) found target-area hair count rose by 20.2 hairs on topical finasteride versus 6.7 on placebo (p<0.001), numerically similar to oral. Peak plasma finasteride was over 100 times lower, and serum DHT fell 34.5% versus 55.6% with oral [9]. The abstract does not state a funder, and 135 of 458 randomized men did not complete. It is 24 weeks long and does not answer the question of rare sexual or psychiatric events. The EMA found no link between the spray and suicidal ideation and left its information unchanged [2].

Risks and unknowns

• Documented: decreased libido, erectile dysfunction, ejaculation disorder; post-marketing depression, suicidal ideation, infertility, testicular pain, male breast cancer; PSA falls, which affects interpretation of prostate screening; at the prostate strength, a higher rate of high-grade prostate cancer in one trial [1].
• Populations at risk: pregnant women must not handle crushed tablets (animal data show genital abnormalities in male fetuses) [1]. The MHRA advises checking for prior depression or suicidal ideation [3].
• Unknown: the frequency and mechanism of persistent symptoms, long-term data on topical use, and controlled data beyond five years.

The @Hoostethics lists

The “ranking looksmaxxing techniques” post (22 October 2026) puts finasteride in D. The “ranking the most cope supplements” post (15 October 2026) puts it in “extremely cope”. We read both posts through the fxtwitter mirror; the tiers come from the attached images, transcribed on 2026-11-08 [12].

• D tier: partly supported. On efficacy, not supported: finasteride has randomized data to five years. As a rank that weighs side-effect uncertainty, the poster has a point, since regulators accept the psychiatric and sexual risk is real, though none withdrew the drug.
• “Extremely cope”: not supported. Finasteride is a regulated prescription drug, not a supplement, and “cope” implies it does not work, which the trials contradict.

Frequently asked questions

Does finasteride regrow hair? In the label trials it increased hair count versus placebo, and it slowed loss in most treated men over five years. Gains reverse after stopping [1].

Is post-finasteride syndrome proven? Persistent sexual symptoms are on the US label as post-marketing reports and acknowledged by the MHRA. A frequency, a cause and a population at risk have not been established [1][3].

Did regulators link finasteride to suicide? The EU confirmed suicidal ideation as a side effect, frequency unknown, and the UK added warnings. Large observational meta-analyses found no significant suicide association [2][3][7][8].

Is topical finasteride safer? It produces far lower blood levels, but evidence is one 24-week trial. Safety for rare events is untested [9].

Sources

1. FDA/openFDA and DailyMed, “Propecia (finasteride) label”, Organon LLC, version 9 (14 Oct 2024). https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=propecia (label text read through the openFDA API).
2. EMA, “Finasteride- and dutasteride-containing medicinal products - referral” (CMDh position 19 Jun 2025; EC decision 22 Aug 2025). https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products
3. MHRA, “Finasteride and dutasteride: updated safety warnings for psychiatric side effects and sexual dysfunction”, Drug Safety Update (11 May 2026). https://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction
4. Finasteride Male Pattern Hair Loss Study Group, “Finasteride in the treatment of men with androgenetic alopecia”, J Am Acad Dermatol (Oct 1998), PMID 9777765 (abstract). https://pubmed.ncbi.nlm.nih.gov/9777765/
5. “Persistent sexual side effects of finasteride: could they be permanent?”, J Sex Med (2013), PMID 22789024 (abstract). https://pubmed.ncbi.nlm.nih.gov/22789024/
6. “Association of 5-alpha-reductase inhibitors with dementia, depression, and suicide”, JAMA Netw Open (2023), PMID 36547981 (abstract). https://pubmed.ncbi.nlm.nih.gov/36547981/
7. “5-alpha-reductase inhibitors and the risk of suicide and neuropsychiatric symptoms: a meta-analysis of observational studies”, Front Urol (2026), PMID 42890027 (abstract). https://pubmed.ncbi.nlm.nih.gov/42890027/
8. “Association of 5-alpha-reductase inhibitors with depression and suicide: a mini systematic review and meta-analysis”, Eur Urol Focus (Sep 2024), PMID 38692949 (abstract). https://pubmed.ncbi.nlm.nih.gov/38692949/
9. “Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial”, J Eur Acad Dermatol Venereol (2022), PMID 34634163 (abstract). https://pubmed.ncbi.nlm.nih.gov/34634163/
10. “Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review”, J Clin Aesthet Dermatol (2016), PMID 27672412 (abstract). https://pubmed.ncbi.nlm.nih.gov/27672412/
11. “Interventions for female pattern hair loss”, Cochrane Database Syst Rev (26 May 2016), PMID 27225981 (abstract). https://pubmed.ncbi.nlm.nih.gov/27225981/
12. @Hoostethics, posts of 22 Oct 2026 and 15 Oct 2026 (tier-list images; text read through the fxtwitter mirror, as X blocked direct access). https://x.com/Hoostethics/status/2113302148750758106 and https://x.com/Hoostethics/status/2110728908735979632
13. “Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin”, Int J Risk Saf Med (2022), PMID 34719438 (abstract). https://pubmed.ncbi.nlm.nih.gov/34719438/
14. “Risk of depression associated with finasteride treatment”, J Clin Psychopharmacol (2021), PMID 33814544 (abstract). https://pubmed.ncbi.nlm.nih.gov/33814544/

This article is information, not medical advice.